ENVB Enveric Biosciences


Data from SEC filings
Employee count

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On September 14, 2021, Enveric Biosciences, Inc. (the “Company”) held its 2021 annual meeting of stockholders (the “Annual Meeting”). Five proposals were included in the notice of Annual Meeting for consideration at the Annual Meeting. At the Annual Meeting, stockholders of the Company voted on the following four proposals, each of which is more fully described in the Company’s definitive proxy statement/prospectus filed with the Securities and Exchange Commission and mailed to stockholders on or about August 6, 2021 (the “Proxy Statement”):

1.the election of five directors to serve until the Company’s 2022 annual meeting of stockholders and until their successors are duly elected and qualified; approve the issuance of shares of the Company’s common stock to MagicMed equity holders in connection with the amalgamation on the terms and conditions of the Amalgamation Agreement; approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers; and ratify the selection of Friedman LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.

Because there were sufficient votes to approve the ENVB Share Issuance Proposal (Proposal 2), adjournment of the Annual Meeting to solicit additional proxies was unnecessary and the adjournment proposal (Proposal 5) was not called to a vote by the Company for approval at the Annual Meeting. The adjournment proposal is described in detail in the Proxy Statement.

Each proposal voted upon at the Annual Meeting and the final voting results are indicated below. As of the close of business on July 30, 2021, the record date for the Annual Meeting, there were 21,432,415 shares of common stock of the Company outstanding. A total of 10,797,302 shares, representing approximately 50.37% of the issued and outstanding shares of common stock of the Company entitled to vote, were present in person or by proxy, constituting a quorum.

1. Election of Directors

For Withheld Broker Non-Vote
David Johnson4,395,856 157,707 6,243,739
George Kegler4,413,161 140,402 6,243,739
Douglas Lind, M.D.4,427,960 125,603 6,243,739
Sol Mayer4,419,998 133,565 6,243,739
Marcus Schabacker, M.D., Ph.D.4,427,523 126,040 6,243,739

2. ENVB Share Issuance Proposal

ForAgainstAbstainBroker Non-Vote

3. Advisory Vote on Compensation of Named Executive Officers

ForAgainstAbstainBroker Non-Vote

4. Ratification of Appointment of Independent Registered Public Accounting Firm